Active, Not Recruiting
Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy
NCT06414577
- Conditions
- Head and Neck Neoplasms, Nasopharyngeal Cancer, Nasopharyngeal Diseases, +8 more
- Locations
-
- SunYat-senU Guangzhou, Guangdong, China